PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32707991-0	2020	In Vitro Assessment of Fluoropyrimidine-Metabolizing Enzymes: Dihydropyrimidine Dehydrogenase, Dihydropyrimidinase, and beta-Ureidopropionase.	2-fluoropyrimidine	23-39	dihydropyrimidinase	Homo sapiens	95-114	
32619063-1	2020	Cancer treatment with a fluoropyrimidine (FP) is often accompanied by severe toxicity that may be dependent on the activity of catalytic enzymes encoded by the DPYD, DPYS, and UPB1 genes.	2-fluoropyrimidine	24-40	dihydropyrimidinase	Homo sapiens	166-170	
28642038-1	2017	Dihydropyrimidinase (DHP, EC 3.5.2.2), encoded by the gene DPYS, is the second enzyme in the catabolic pathway of pyrimidine and of fluoropyrimidine drugs such as 5-fluorouracil, which are commonly used in anticancer treatment; DHP catalyzes the hydrolytic ring opening of dihydrouracil and dihydro-5-fluorouracil.	2-fluoropyrimidine	132-148	dihydropyrimidinase	Homo sapiens	0-19	
28642038-1	2017	Dihydropyrimidinase (DHP, EC 3.5.2.2), encoded by the gene DPYS, is the second enzyme in the catabolic pathway of pyrimidine and of fluoropyrimidine drugs such as 5-fluorouracil, which are commonly used in anticancer treatment; DHP catalyzes the hydrolytic ring opening of dihydrouracil and dihydro-5-fluorouracil.	2-fluoropyrimidine	132-148	dihydropyrimidinase	Homo sapiens	21-24	
28642038-1	2017	Dihydropyrimidinase (DHP, EC 3.5.2.2), encoded by the gene DPYS, is the second enzyme in the catabolic pathway of pyrimidine and of fluoropyrimidine drugs such as 5-fluorouracil, which are commonly used in anticancer treatment; DHP catalyzes the hydrolytic ring opening of dihydrouracil and dihydro-5-fluorouracil.	2-fluoropyrimidine	132-148	dihydropyrimidinase	Homo sapiens	59-63	
28642038-1	2017	Dihydropyrimidinase (DHP, EC 3.5.2.2), encoded by the gene DPYS, is the second enzyme in the catabolic pathway of pyrimidine and of fluoropyrimidine drugs such as 5-fluorouracil, which are commonly used in anticancer treatment; DHP catalyzes the hydrolytic ring opening of dihydrouracil and dihydro-5-fluorouracil.	2-fluoropyrimidine	132-148	dihydropyrimidinase	Homo sapiens	228-231	
28642038-2	2017	DPYS mutations are known to contribute to interindividual variations in the toxicity of fluoropyrimidine drugs, but the functional characterization of DHP allelic variants remains inadequate.	2-fluoropyrimidine	88-104	dihydropyrimidinase	Homo sapiens	0-4	
28642038-8	2017	Thus, detection of DPYS genetic polymorphisms might facilitate the prediction severe adverse effects of fluoropyrimidine-based treatments.	2-fluoropyrimidine	104-120	dihydropyrimidinase	Homo sapiens	19-23	
26244261-1	2015	AIMS: To assess the association of DPYS and UPB1 genetic variation, encoding the catabolic enzymes downstream of dihydropyrimidine dehydrogenase, with early-onset toxicity from fluoropyrimidine-based chemotherapy.	2-fluoropyrimidine	177-193	dihydropyrimidinase	Homo sapiens	35-39	
25915935-1	2015	Dihydropyrimidinase (DHP) is the second enzyme in the catabolic pathway of uracil, thymine, and chemotherapeutic fluoropyrimidine agents such as 5-fluorouracil (5-FU).	2-fluoropyrimidine	113-129	dihydropyrimidinase	Homo sapiens	0-19	
25915935-1	2015	Dihydropyrimidinase (DHP) is the second enzyme in the catabolic pathway of uracil, thymine, and chemotherapeutic fluoropyrimidine agents such as 5-fluorouracil (5-FU).	2-fluoropyrimidine	113-129	dihydropyrimidinase	Homo sapiens	21-24	
25915935-9	2015	This is the first report of a DHP-deficient patient with DPYS compound heterozygous polymorphisms who was treated with a fluoropyrimidine, and our findings suggest that polymorphisms in the DPYS gene are pharmacogenomic markers associated with severe 5-FU toxicity in Japanese patients.	2-fluoropyrimidine	121-137	dihydropyrimidinase	Homo sapiens	57-61	
25915935-9	2015	This is the first report of a DHP-deficient patient with DPYS compound heterozygous polymorphisms who was treated with a fluoropyrimidine, and our findings suggest that polymorphisms in the DPYS gene are pharmacogenomic markers associated with severe 5-FU toxicity in Japanese patients.	2-fluoropyrimidine	121-137	dihydropyrimidinase	Homo sapiens	190-194	
19649633-0	2010	Contribution of dihydropyrimidinase gene alterations to the development of serious toxicity in fluoropyrimidine-treated cancer patients.	2-fluoropyrimidine	95-111	dihydropyrimidinase	Homo sapiens	16-35